$5.28
+0.06 (+1.15%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AVIR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
33 interventional · 4 with posted results
Held by 8 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, +3 more) · FINRA short interest 18.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVNCT07037277Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24Randomized · Single-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir | HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C | 880 | Dec 2026 | ≤ 134 d | 2026-06-29 |
| Study of AT-587 in Healthy SubjectsNCT07728487Proportions (active vs. Placebo) of subjects experiencing treatment-emergent adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Recruiting | Drug: AT-587 · Other: Placebo | Hepatitis E | 62 | Dec 2026 | ≤ 134 d | 2026-07-27 |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVNCT06868264Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.Randomized · Single-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL) | HEPATITIS C VIRUS CHRONIC INFECTION | 880 | Sep 2026 | ≤ 42 d | 2025-12-05 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or MethadoneNCT07314346Effect of BEM/RZR on PK of buprenorphine,norbuprenorphine and naloxoneNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR | Healthy Volunteer Study | 32 | Aug 2026 | ≤ 12 d | 2026-07-16 |
| Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic FunctionNCT06911320Pharmacokinetics (PK) of BEM/RZR Maximum plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination | Healthy Volunteer Study, Hepatic Impairment, Renal Impairment | 28 | 2026-04-30actual | — | 2026-07-31 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)NCT07272889PK of EE/LNG (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR), Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) | Healthy Volunteer Study | 24 | 2026-02-17actual | — | 2026-04-13 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and RosuvastatinNCT06921941PK of Digoxin and Rosuvastatin (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR | Healthy Volunteer Study | 38 | 2025-07-02actual | — | 2025-08-29 |
| Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/RuzasvirNCT07007806PK of BEM/RZROpen-label · Treatment | Phase 1 | Completed | Drug: Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting, Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole, Treatment E-Omeprazole 40 mg administered fasting, Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole | Healthy Volunteer Study | 20 | 2025-06-28actual | — | 2025-08-29 |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCVNCT05904470results2025-10-21Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Bemnifosbuvir, Ruzasvir | Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV | 275 | 2024-12-09actual | — | 2025-10-21 |
| Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and RuzasvirNCT06204679Pharmacokinetics (PK) of FDC compared to reference:(Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions | Healthy Volunteer Study | 42 | 2024-08-25actual | — | 2024-09-19 |
| Study of AT-527 in Subjects With Normal and Impaired Renal FunctionNCT05618314Pharmacokinetics (PK) of AT-527 Maximum plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AT-527, AT-527, AT-527 and Probenecid | Healthy Volunteer, Renal Impairment | 36 | 2024-06-15actual | — | 2024-07-31 |
| Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/RuzasvirNCT06356194PK of Biktarvy (BIK: Bictegravir, tenofovir alafenamide, emtricitabine) on the pharmacokinetics (PK) of Bemnifosbuvir (BEM) and Ruzasvir (RZR).Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK, Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. | Healthy Volunteer Study | 28 | 2024-05-30actual | — | 2024-07-31 |
| SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19NCT05629962results2025-06-13Percentage of Subjects Hospitalized for Any Cause or Died Due to Any CauseRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Bemnifosbuvir (BEM), Placebo | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19 | 2,285 | 2024-04-25actual | — | 2025-06-13 |
| Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic FunctionNCT05724693Pharmacokinetics (PK) of BEM Maximum plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Bemnifosbuvir (BEM) | Healthy Volunteer, Hepatic Impairment | 39 | 2024-04-23actual | — | 2024-07-31 |
| Study of Bemnifosbuvir on Cardiac Repolarization in Healthy SubjectsNCT05905484Placebo-corrected (Δ) change-from-baseline QTc (ΔΔQTc).Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Bemnifosbuvir (BEM), Placebo, Moxifloxacin | Healthy Volunteer Study | 35 | 2023-05-31actual | — | 2023-06-15 |
| The Study of Bemnifosbuvir in Healthy Japanese SubjectsNCT05905497Pharmacokinetics (PK) of BEM Maximum plasma concentration (Cmax)Open-label · Treatment | Phase 1 | Completed | Drug: Bemnifosbuvir (BEM) | Healthy Volunteer Study | 14 | 2023-05-19actual | — | 2023-06-15 |
| Study of AT-752 in Healthy Subjects in a Dengue Human Challenge ModelNCT05366439Mean quantitative RNAemia (peak and duration and area under the plasma concentration versus time curve [AUC])Randomized · Triple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to deprioritize the dengue program | Drug: AT-752, Placebo Comparator | Dengue | 5 | 2023-03-16actual | — | 2023-04-21 |
| Drug-drug Interaction Study of Ruzasvir and BemnifosbuvirNCT05731843Pharmacokinetics (PK) of BEMNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM | Healthy Volunteer Study | 32 | 2023-03-15actual | — | 2023-06-01 |
| Study of AT-752 in Patients With Dengue InfectionNCT05466240results2024-03-05Change in Dengue (DENV) Viral Load From BaselineRandomized · Triple-masked · TreatmentStudy Protocol: Original Protocol ↗ · Study Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to deprioritize the dengue program | Drug: AT-752, Placebo | Dengue Fever | 21 | 2023-01-19actual | — | 2024-03-05 |
| Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a MealNCT05256732Pharmacokinetics (PK) of AT-527Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: AT-527 fasted, AT-527 fed, AT-527, AT-527 single dose · Other: Placebo Comparator fasted, Placebo Comparator fed | Healthy Volunteer Study | 136 | 2022-08-23actual | — | 2022-10-18 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected SubjectsNCT04309734Incidence of Treatment-Emergent Adverse EventsRandomized · Triple-masked · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Withdrawn prior to study initiation. | Drug: AT-777, Placebo, AT-527 | Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C, Hepatitis C Virus Infection, HCV Infection | 0 | Jun 2022 | — | 2022-06-08 |
| Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital SettingNCT04396106results2023-03-09Proportions (Active vs. Placebo) of Subjects With Progressive Respiratory Insufficiency (PRI) on or Before Day 14.Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study closed out early due to evolving COVID-19 standard of care | Drug: AT-527, AT-527 · Other: Placebo, Placebo | COVID-19 | 83 | 2022-01-10actual | — | 2023-03-09 |
| Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)NCT05154123To evaluate the effect of co-administration of AT-527 on the single-dose pharmacokinetics (PK) of rosuvastatinNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Drug: AT-527 + rosuvastatin, AT-527 + rosuvastatin | Healthy Volunteer Study | 29 | 2021-12-23actual | — | 2022-02-25 |
| Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)NCT05137626To determine the effect of AT-527 on the single-dose pharmacokinetics (PK) of digoxinNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AT-527 + digoxin, AT-527 + digoxin | Healthy Volunteers Study | 29 | 2021-12-12actual | — | 2022-02-28 |
| Study of AT-752 in Healthy SubjectsNCT04722627Proportions (active vs. Placebo) of subjects experiencing treatment-emergent adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: AT-752, Placebo | Dengue | 65 | 2021-11-14actual | — | 2022-10-17 |
| Study of AT-527 in Healthy Subjects (R07496998)NCT04711187Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events.Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: AT-527 Formulation 1, AT-527 Formulation 2 · Other: Placebo Comparator | Healthy Volunteer Study | 81 | 2021-09-15actual | — | 2022-02-25 |
| Bronchopulmonary PK of AT-527 (R07496998)NCT04877769Concentrations of AT-527 in epithelial lining fluidNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AT-527 | Healthy Volunteer Study | 24 | 2021-08-31actual | — | 2022-02-25 |
| Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)NCT05004415Mass BalanceOpen-label · Treatment | Phase 1 | Completed | Drug: AT-527 (R07496998) | Healthy Volunteer Study | 6 | 2021-08-12actual | — | 2022-02-25 |
| Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)NCT04865445Pharmacokinetics (PK) of midazolamNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AT-527 550 mg + midazolam, AT-527 550 mg + midazolam | Healthy Volunteer Study | 24 | 2021-05-15actual | — | 2021-07-29 |
| Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)NCT04849299Pharmacokinetics (PK) of AT-527 (R07496998): CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: AT-527 550 mg + cyclosporine, AT-527 550 mg + cyclosporine | Healthy Volunteer Study | 24 | 2021-05-10actual | — | 2021-08-02 |
| Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527NCT04784000Pharmacokinetics (PK) of AT-527 (RO7496998)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Period 1: AT-527 550 mg, Period 2: carbamazepine, Period 3: AT-527 550 mg + carbamazepine, Period 3: AT-527 1100 mg + carbamazepine | Healthy Volunteer Study | 20 | 2021-04-10actual | — | 2021-07-29 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) InfectionNCT04019717Proportion of subjects achieving sustained virologic response (SVR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: AT-527, Daclatasvir | Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C, Hepatitis C Virus Infection, HCV Infection | 10 | 2020-01-29actual | — | 2020-05-04 |
| Study of AT-527 in Healthy and HCV-Infected SubjectsNCT03219957Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: AT-527 · Other: Placebo Comparator | Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic | 88 | 2018-06-20actual | — | 2020-02-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19